CLINICAL NEUROSCIENCE AND NEUROPATHOLOGYDefective Fas ligand production in lymphocytes from MS patientsMacchi, Beatrice1,3, CA; Matteucci, Claudia2; Nocentini, Ugo1,3; Tacconi, Santina2; Pagnini, Veronica2; Mastino, Antonio4; Caltagirone, Carlo1,3Author Information Departments of 1Neuroscience and 2Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via di Tor Vergata 135 00133 Rome; 3IRCCS, Clinica S. Lucia, Rome; 4Department of Microbiological, Genetic and Molecular Sciences, University of Messina, Messina, Italy CA,1Corresponding Author and Address Received 3 October 2001; accepted 24 October 2001 Neuroreport: December 21st, 2001 - Volume 12 - Issue 18 - p 4113-4116 Buy SDC Abstract In the present transectional study, Fas ligand (Fas-L) levels, either in membrane or in soluble form, in cells from multiple sclerosis (MS) patients were investigated. Expression of Fas was evaluated after PHA stimulation of peripheral blood mononuclear cells from MS patients with relapsing-remitting or secondary-progressive disease, and in healthy donors. There was statistically significant decreased expression (p = 0.001), as well as release of Fas-L, (p = 0.045) in lymphocytes from MS patients, in comparison with healthy donors. Moreover, levels of Fas-L production were inversely correlated with the EDSS scores of patients in an highly significant way. Impairment of Fas-L release in stimulated PBMC from MS patients might influence the ability to eliminate autoreactive clones in vivo. © 2001 Lippincott Williams & Wilkins, Inc.